The European Commission (EC) has approved a higher dosage of obesity drug Wegovy which has proved it can help adults lose weight more effectively.  Final approval has been granted to a new 7.2mg once-weekly maintenance dose of Wegovy (semaglutide injection), giving doctors another treatment option alongside the previous 2.4mg dose.   Novo Nordisk has applied for approval […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!